10-Q: Lisata Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

Lisata Therapeutics reported a net loss of $5.0 million for the second quarter of 2024, while highlighting ongoing clinical trials for its lead drug candidate, certepetide.

Summary

• Lisata Therapeutics, a clinical-stage pharmaceutical company, reported a net loss of $5.0 million for the three months ended June 30, 2024, compared to a net loss of $4.0 million for the same period in 2023.
• The company's operating expenses decreased to $5.5 million in Q2 2024 from $6.9 million in Q2 2023, primarily due to reduced research and development costs and lower general and administrative expenses.
• Research and development expenses were $2.6 million for the three months ended June 30, 2024, compared to $3.2 million for the same period in 2023.
• General and administrative expenses decreased to $2.9 million in Q2 2024 from $3.7 million in Q2 2023.
• For the six months ended June 30, 2024, the net loss was $10.4 million, compared to $10.2 million for the same period in 2023.
• The company's cash, cash equivalents, and marketable securities totaled approximately $38.3 million as of June 30, 2024.
• Lisata is focused on developing certepetide, a drug designed to enhance the delivery of anti-cancer therapies to solid tumors.
• Certepetide is currently being evaluated in multiple Phase 2 clinical trials for various solid tumor types.
• The company believes its current cash and marketable securities will fund operations for at least the next 12 months.

Sentiment

Score: 5

Explanation: The document presents a mixed picture. While the company is making progress in its clinical trials and has reduced operating expenses, the increased net loss and the need for potential future capital raises temper the positive aspects. The company's financial position is stable for the next 12 months, but there are risks associated with its long-term financial sustainability.

Positives

• Operating expenses decreased by $1.4 million in Q2 2024 compared to Q2 2023.
• Research and development expenses saw a reduction of $0.6 million in Q2 2024 compared to Q2 2023.
• General and administrative expenses decreased by $0.8 million in Q2 2024 compared to Q2 2023.
• The company has a cash runway of at least 12 months based on current cash and marketable securities.
• The company is actively progressing multiple Phase 2 clinical trials for certepetide.

Negatives

• The company reported a net loss of $5.0 million for the second quarter of 2024.
• The company has a history of operating losses and liquidity challenges.
• The company's ability to raise capital may be difficult due to its history of operating losses.
• The company is subject to limitations on the amount of equity it can sell under its ATM agreement due to its public float.

Risks

• The company's ability to obtain sufficient capital or strategic business arrangements to fund operations and expansion plans is a risk.
• There is a risk that a market may not be established for the company's products.
• The company's ability to obtain and maintain governmental licenses and comply with healthcare laws is a risk.
• The company's ability to commercialize products without infringing upon third-party patents is a risk.
• The company's ability to complete planned clinical trials on time is subject to delays.
• Future public health crises could impact the company's business, clinical trials, and financial condition.
• The company's history of operating losses and liquidity challenges may make it difficult to raise capital on acceptable terms.

Future Outlook

The company believes that its current cash and marketable securities will enable it to fund current operating expenses for at least the next 12 months. The company will also continue to seek grants and other sources of non-dilutive funding.

Management Comments

• The company's leadership team has decades of collective biopharmaceutical and pharmaceutical product development experience.
• The company's goal is to develop and commercialize products that address important unmet medical needs.

Industry Context

Lisata Therapeutics is operating in the competitive pharmaceutical and biotechnology industry, focusing on developing novel therapies for solid tumors. The company's approach of enhancing drug delivery through the CendR active transport mechanism is a unique strategy in the oncology space. The company is competing with other companies developing cancer therapies, including chemotherapies, immunotherapies, and RNA-based therapeutics.

Comparison to Industry Standards

• The company's reported net loss of $5.0 million for Q2 2024 is typical for a clinical-stage biotech company that is still in the development phase and not yet generating revenue from product sales.
• The reduction in operating expenses, particularly in R&D and G&A, is a positive sign of cost management, which is crucial for companies with limited revenue.
• The company's cash position of $38.3 million is relatively healthy for a company of its size and stage, providing a runway of at least 12 months, which is a common benchmark for biotech companies.
• The company's focus on certepetide and its unique mechanism of action differentiates it from many other oncology companies, which are often focused on more traditional approaches.
• The company's clinical trial progress, with multiple Phase 2 studies underway, is in line with industry standards for companies at this stage of development.
• Compared to companies like BioNTech or Moderna, which have commercialized products, Lisata is still in the clinical development phase and therefore has higher operating expenses and no revenue.
• Compared to companies like Adaptimmune or Kite Pharma, which are focused on cell therapies, Lisata's approach of enhancing drug delivery is a different strategy within the oncology space.

Management Changes

Legal Proceedings

• The company settled a legal dispute with Lingmed, paying $0.5 million and agreeing to future milestone payments.

Stakeholder Impact

• Shareholders may be concerned about the increased net loss and the potential need for additional capital raises.
• Employees may be affected by the company's cost-cutting measures and potential future changes.
• Patients may benefit from the company's development of new cancer therapies.
• Creditors may be concerned about the company's history of operating losses and liquidity challenges.

Next Steps

• The company will continue to advance its clinical trials for certepetide.
• The company will seek additional funding through various means, including grants and potential capital raises.
• The company will continue to explore out-licensing and partnering opportunities.

Key Dates

Keywords

Lisata Therapeutics, certepetide, clinical trials, pharmaceutical, oncology, cancer, tumor, R&D, financial results, biotechnology